These studies reported the association between CD169+ macrophages and CD8+ T cells in patients with gastric cancer, hepatocellular carcinoma, colorectal carcinoma, esophageal cancer, bladder cancer, endometrial carcinoma, malignant melanoma, breast cancer, or oral squamous cell carcinoma. Here, SIGLEC1 is linked to breast carcinoma.